Non-Hodgkin's Lymphoma
| TREATMENT REGIMENS | |||||
|---|---|---|---|---|---|
| High-dose Methotrexate administration | |||||
| High-dose Methotrexate | |||||
| DRC | |||||
| Rituximab | |||||
| Indolent Lymphoma | |||||
| Obinutuzumab + bendamustine | |||||
| Obinutuzumab maintenance | |||||
| R-bendamustine | |||||
| R-CVP | |||||
| R-CHOP | |||||
| Rituximab | |||||
| Rituximab maintenance | |||||
| Mantle cell lymphoma | |||||
| R-Hyper CVAD | |||||
| B-cell lymphoma | |||||
| R-CHOP | |||||
| GDP | |||||
| R-GDP | |||||
| ESHAP | |||||
| R-ESHAP | |||||
| ICE | |||||
| R-ICE | |||||
| DHAP | |||||
| R-DHAP | |||||
| R-GEMOX | |||||
| Dose-adjusted EPOCH-R | |||||
| R-CEOP | |||||
| Burkitt lymphoma | |||||
| R-Hyper CVAD | |||||
| T-Cell Lymphoma | |||||
| Brentuximab vedotin + CHP | |||||
| CHOP | |||||
| Brentuximab vedotin | |||||
| Romidepsin | |||||
| Mogamulizumab | |||||
| Primary CNS lymphoma | |||||
| AIDS-Related Lymphoma | |||||
Groupe d'étude en oncologie du Québec